

Raoul Orvieto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/723044/publications.pdf>

Version: 2024-02-01

167
papers

4,053
citations

136740

32
h-index

155451

55
g-index

219
all docs

219
docs citations

219
times ranked

3797
citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, 121.	1.4	330
2	Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility. <i>World Journal of Men's Health</i> , 2019, 37, 296.	1.7	256
3	Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. <i>Fertility and Sterility</i> , 2016, 106, 467-474.	0.5	197
4	Is the oocyte quality affected by endometriosis? A review of the literature. <i>Journal of Ovarian Research</i> , 2017, 10, 43.	1.3	146
5	First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination. <i>Fertility and Sterility</i> , 2018, 109, 48-53.	0.5	108
6	Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle?. <i>Reproductive Biology and Endocrinology</i> , 2021, 19, 69.	1.4	99
7	Can we eliminate severe ovarian hyperstimulation syndrome?. <i>Human Reproduction</i> , 2005, 20, 320-322.	0.4	95
8	Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. <i>Fertility and Sterility</i> , 2014, 102, 488-495.e3.	0.5	95
9	Does the endometrial receptivity array really provide personalized embryo transfer?. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 1301-1305.	1.2	92
10	The "immunologic theory" of preeclampsia revisited: a lesson from donor oocyte gestations. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 383.e1-383.e5.	0.7	90
11	Is the hypothesis of preimplantation genetic screening (PGS) still supportable? A review. <i>Journal of Ovarian Research</i> , 2017, 10, 21.	1.3	88
12	COVID-19 and assisted reproductive technology services: repercussions for patients and proposal for individualized clinical management. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, 45.	1.4	81
13	Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. <i>Journal of Assisted Reproduction and Genetics</i> , 2019, 36, 2207-2215.	1.2	77
14	The influence of body mass index on in vitro fertilization outcome. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 104, 53-55.	1.0	71
15	Triggering final follicular maturation- hCG, GnRH-agonist or both, when and to whom?. <i>Journal of Ovarian Research</i> , 2015, 8, 60.	1.3	71
16	Bisphenol A, oocyte maturation, implantation, and IVF outcome: review of animal and human data. <i>Reproductive BioMedicine Online</i> , 2014, 29, 404-410.	1.1	68
17	Does BPA alter steroid hormone synthesis in human granulosa cells <i>in vitro</i> ?. <i>Human Reproduction</i> , 2016, 31, 1562-1569.	0.4	60
18	Elevated Levels of FMR1 mRNA in Granulosa Cells Are Associated with Low Ovarian Reserve in FMR1 Premutation Carriers. <i>PLoS ONE</i> , 2014, 9, e105121.	1.1	57

#	ARTICLE	IF	CITATIONS
19	C-reactive protein levels in patients undergoing controlled ovarian hyperstimulation for IVF cycle. <i>Human Reproduction</i> , 2004, 19, 357-359.	0.4	50
20	Prediction of ovarian hyperstimulation syndrome: Challenging the estradiol mythos. <i>Human Reproduction</i> , 2003, 18, 665-667.	0.4	49
21	GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate. <i>Reproductive BioMedicine Online</i> , 2013, 26, 4-8.	1.1	46
22	Does mRNA SARS-CoV-2 vaccine detrimentally affect male fertility, as reflected by semen analysis?. <i>Reproductive BioMedicine Online</i> , 2022, 44, 145-149.	1.1	46
23	Do human embryos have the ability of self-correction?. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, 98.	1.4	45
24	GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity. <i>Fertility and Sterility</i> , 2008, 90, 1294-1296.	0.5	44
25	Controlled Ovarian Hyperstimulation—An Inflammatory State. <i>Journal of the Society for Gynecologic Investigation</i> , 2004, 11, 424-426.	1.9	42
26	The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for <i>in vitro</i> fertilization. <i>Gynecological Endocrinology</i> , 2007, 23, 72-75.	0.7	41
27	Standard human chorionic gonadotropin versus double trigger for final oocyte maturation results in different granulosa cells gene expressions: a pilot study. <i>Fertility and Sterility</i> , 2016, 106, 653-659.e1.	0.5	41
28	Should pre-implantation genetic screening be implemented to routine clinical practice?. <i>Gynecological Endocrinology</i> , 2016, 32, 506-508.	0.7	41
29	Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma. <i>Journal of Ovarian Research</i> , 2013, 6, 77.	1.3	40
30	Does salpingectomy affect the ipsilateral ovarian response to gonadotropin during <i>in vitro</i> fertilization—embryo transfer cycles?. <i>Fertility and Sterility</i> , 2011, 95, 1842-1844.	0.5	39
31	Is the modified natural <i>in vitro</i> fertilization cycle justified in patients with “genuine” poor response to controlled ovarian hyperstimulation?. <i>Fertility and Sterility</i> , 2014, 101, 1624-1628.	0.5	39
32	The effect of coronavirus disease 2019 immunity on frozen-thawed embryo transfer cycles outcome. <i>Fertility and Sterility</i> , 2022, 117, 974-979.	0.5	39
33	Outcome of immature oocytes collection of 119 cancer patients during ovarian tissue harvesting for fertility preservation. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 851-856.	1.2	37
34	Should ICSI be implemented during IVF to all advanced-age patients with non-male factor subfertility?. <i>Reproductive Biology and Endocrinology</i> , 2019, 17, 30.	1.4	35
35	CAUTION: PRENATAL CLUBFOOT CAN BE BOTH A TRANSIENT AND A LATE-ONSET PHENOMENON. , 1997, 17, 457-460.		34
36	Pre-implantation genetic diagnosis—should we use ICSI for all?. <i>Journal of Assisted Reproduction and Genetics</i> , 2017, 34, 1179-1183.	1.2	31

#	ARTICLE	IF	CITATIONS
37	Is severe OHSS associated with adverse pregnancy outcomes? Evidence from a case-control study. <i>Reproductive BioMedicine Online</i> , 2014, 29, 216-221.	1.1	30
38	Does double trigger (GnRH-agonist+hCG) improve outcome in poor responders undergoing IVF-ET cycle? A pilot study. <i>Gynecological Endocrinology</i> , 2019, 35, 628-630.	0.7	30
39	Perinatal outcome after fetal reduction from twin to singleton: to reduce or not to reduce?. <i>Fertility and Sterility</i> , 2015, 103, 428-432.	0.5	29
40	Machine learning vs. classic statistics for the prediction of IVF outcomes. <i>Journal of Assisted Reproduction and Genetics</i> , 2020, 37, 2405-2412.	1.2	29
41	Reproductive Outcome Is Favorable After Laparoscopic Resection of Bladder Endometriosis. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 781-786.	0.3	28
42	Endometrial polyps during menopause, characterization and significance. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1999, 78, 883-886.	1.3	26
43	Should preimplantation genetic screening (PGS) be implemented to routine IVF practice?. <i>Journal of Assisted Reproduction and Genetics</i> , 2016, 33, 1445-1448.	1.2	26
44	Dibutyl phthalate impairs steroidogenesis and a subset of LH-dependent genes in cultured human mural granulosa cell in vitro. <i>Reproductive Toxicology</i> , 2017, 69, 13-18.	1.3	24
45	Possible risk for cancer among children born following assisted reproductive technology in Israel. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26292.	0.8	24
46	Preimplantation genetic testing for aneuploidy (PGT-A) finally revealed. <i>Journal of Assisted Reproduction and Genetics</i> , 2020, 37, 669-672.	1.2	24
47	What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?. <i>Fertility and Sterility</i> , 2009, 91, 1466-1468.	0.5	23
48	Does bariatric surgery improve ovarian stimulation characteristics, oocyte yield, or embryo quality?. <i>Journal of Ovarian Research</i> , 2014, 7, 116.	1.3	23
49	Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation. <i>Gynecological Endocrinology</i> , 2006, 22, 437-440.	0.7	22
50	Is Embryo Cryopreservation Causing Macrosomia and What Else?. <i>Frontiers in Endocrinology</i> , 2020, 11, 19.	1.5	22
51	We have reached a dead end for preimplantation genetic testing for aneuploidy. <i>Human Reproduction</i> , 2022, 37, 2730-2734.	0.4	22
52	Attempts to improve human ovarian transplantation outcomes of needle-immersed vitrification and slow-freezing by host and graft treatments. <i>Journal of Assisted Reproduction and Genetics</i> , 2017, 34, 633-644.	1.2	21
53	Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. <i>Reproductive Biology and Endocrinology</i> , 2021, 19, 91.	1.4	21
54	Controlled Ovarian Hyperstimulation: A State of Neutrophil Activation. <i>American Journal of Reproductive Immunology</i> , 1999, 42, 288-291.	1.2	20

#	ARTICLE	IF	CITATIONS
55	Does methotrexate treatment for ectopic pregnancy influence the patient's performance during a subsequent in vitro fertilization/embryo transfer cycle?. <i>Fertility and Sterility</i> , 2007, 88, 1685-1686.	0.5	19
56	Follitropin- α (Gonal-F) versus follitropin- β (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?. <i>Fertility and Sterility</i> , 2009, 91, 1522-1525.	0.5	19
57	FMR6 may play a role in the pathogenesis of fragile X-associated premature ovarian insufficiency. <i>Gynecological Endocrinology</i> , 2016, 32, 334-337.	0.7	19
58	HMG versus recombinant FSH plus recombinant LH in ovarian stimulation for IVF: does the source of LH preparation matter?. <i>Reproductive BioMedicine Online</i> , 2019, 39, 1001-1006.	1.1	19
59	Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue?. <i>Gynecological Endocrinology</i> , 2012, 28, 422-424.	0.7	17
60	Predictors of reproductive outcomes following myomectomy for intramural fibroids. <i>Reproductive BioMedicine Online</i> , 2019, 39, 484-491.	1.1	17
61	GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels. <i>Gynecological Endocrinology</i> , 2013, 29, 843-845.	0.7	16
62	The expected cumulative incidence of live birth for patients starting IVF treatment at age 41 years or older. <i>Reproductive BioMedicine Online</i> , 2018, 37, 533-541.	1.1	16
63	Influence of seasonal variation on in vitro fertilization success. <i>PLoS ONE</i> , 2018, 13, e0199210.	1.1	16
64	Interleukin-2 Production in Whole Blood Cell Cultures of Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproduction Technology Cycles. <i>American Journal of Reproductive Immunology</i> , 2003, 50, 220-223.	1.2	15
65	Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues?. <i>Fertility and Sterility</i> , 2008, 90, 1297-1300.	0.5	15
66	The association between follicle size and oocyte development as a function of final follicular maturation triggering. <i>Reproductive BioMedicine Online</i> , 2020, 40, 887-893.	1.1	15
67	Is there still a rationale for non-invasive PGT-A by analysis of cell-free DNA released by human embryos into culture medium?. <i>Human Reproduction</i> , 2021, 36, 1186-1190.	0.4	15
68	Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study. <i>Fertility and Sterility</i> , 2002, 78, 1268-1271.	0.5	14
69	The prostaglandin transporter (PGT) as a potential mediator of ovulation. <i>Science Translational Medicine</i> , 2016, 8, 338ra68.	5.8	14
70	The myths surrounding mild stimulation in vitro fertilization (IVF). <i>Reproductive Biology and Endocrinology</i> , 2017, 15, 48.	1.4	14
71	Outcomes of singleton versus twin pregnancies in the fifth and sixth decades. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 231, 255-261.	0.5	14
72	The effect of body mass index (BMI) and gestational weight gain on adverse obstetrical outcomes in pregnancies following assisted reproductive technology as compared to spontaneously conceived pregnancies. <i>Obesity Research and Clinical Practice</i> , 2019, 13, 150-155.	0.8	14

#	ARTICLE	IF	CITATIONS
73	Does daily co administration of gonadotropins and letrozole during the ovarian stimulation improve IVF outcome for poor and sub optimal responders?. Journal of Ovarian Research, 2020, 13, 66.	1.3	14
74	Can Oocyte Diameter Predict Embryo Quality?. Reproductive Sciences, 2021, 28, 904-908.	1.1	14
75	Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines. Frontiers in Endocrinology, 2021, 12, 587051.	1.5	14
76	Controlled Ovarian Hyperstimulation - A State of Endothelial Activation1. American Journal of Reproductive Immunology, 2000, 44, 257-260.	1.2	13
77	Feasibility and efficacy of repeated hysteroscopic cesarean niche resection. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 217, 12-17.	0.5	11
78	Fertility success rates in patients with secondary infertility and symptomatic cesarean scar niche undergoing hysteroscopic niche resection. Gynecological Endocrinology, 2020, 36, 912-916.	0.7	11
79	Commentary on two recently published formal guidelines on management of "mosaic" embryos after preimplantation genetic testing for aneuploidy (PGT-A). Reproductive Biology and Endocrinology, 2021, 19, 23.	1.4	11
80	Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis. Reproductive Biology and Endocrinology, 2021, 19, 51.	1.4	11
81	The neglected members of the family: non-BRCA mutations in the Fanconi anemia/BRCA pathway and reproduction. Human Reproduction Update, 2022, 28, 296-311.	5.2	11
82	Lack of Association between Varicocele and Angiokeratoma of the Scrotum (Fordyce). Military Medicine, 1994, 159, 523-524.	0.4	10
83	Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality. Fertility and Sterility, 2009, 91, 1398-1400.	0.5	10
84	Pregnancy outcome in severe OHSS patients following ascitic/pleural fluid drainage. Journal of Ovarian Research, 2014, 7, 56.	1.3	10
85	In Vitro Fertilization Outcomes After Placement of Essure Microinserts in Patients With Hydrosalpinges Who Previously Failed In Vitro Fertilization Treatment: A Multicenter Study. Journal of Minimally Invasive Gynecology, 2016, 23, 939-943.	0.3	10
86	Should We Offer In Vitro Fertilization to Couples with Unexplained Recurrent Pregnancy Loss?. Journal of Clinical Medicine, 2019, 8, 2001.	1.0	10
87	Ovarian cysts and cyclic hormone replacement therapy: is there an association?. Acta Obstetrica Et Gynecologica Scandinavica, 1997, 76, 563-566.	1.3	9
88	Development of human fetal follicles in an immunodeficient mouse. Journal of Assisted Reproduction and Genetics, 2000, 17, 393-397.	1.2	9
89	Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol. Gynecological Endocrinology, 2007, 23, 494-496.	0.7	9
90	Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?. Fertility and Sterility, 2008, 89, 736-737.	0.5	9

#	ARTICLE	IF	CITATIONS
91	Triggering final follicular maturationâ€”hCG, GnRH-agonist or both, when and to whom?. <i>Journal of Assisted Reproduction and Genetics</i> , 2016, 33, 1415-1416.	1.2	9
92	Hysteroscopically guided transvaginal ultrasound tubal catheterizationâ€”a novel office procedure. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 204, 113-116.	0.5	9
93	Preimplantation genetic diagnosis versus prenatal diagnosisâ€”decision-making among pregnant FMR1 premutation carriers. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 2071-2075.	1.2	9
94	Assessment of a double freezing approach in the management of surplus embryos in IVF. <i>Reproductive BioMedicine Online</i> , 2019, 38, 517-519.	1.1	9
95	The reproducibility of trophectoderm biopsies â€” The chaos behind preimplantation genetic testing for aneuploidy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 254, 57-58.	0.5	9
96	Obstetric, neonatal and child development outcomes following assisted hatching treatment: a retrospective cohort study. <i>Gynecological Endocrinology</i> , 2021, 37, 41-45.	0.7	9
97	The uncertain science of preimplantation and prenatal genetic testing. <i>Nature Medicine</i> , 2022, 28, 442-444.	15.2	9
98	Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1998, 77, 327-329.	1.3	8
99	Ovarian androgens but not estrogens correlate with the degree of systemic inflammation observed during controlled ovarian hyperstimulation. <i>Gynecological Endocrinology</i> , 2005, 21, 170-173.	0.7	8
100	GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori. <i>Fertility and Sterility</i> , 2009, 91, 1378-1380.	0.5	8
101	Ovarian reserve after uterine artery embolization in women with morbidly adherent placenta: A cohort study. <i>PLoS ONE</i> , 2018, 13, e0208139.	1.1	8
102	Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, 50.	1.4	8
103	Cognitive achievements in school-age children born following assisted reproductive technology treatments: A prospective study. <i>Early Human Development</i> , 2021, 155, 105327.	0.8	8
104	Case Report: Delayed intra-abdominal bleeding following trans-vaginal ultrasonography guided oocyte retrieval for in vitro fertilization in patients at risk for thrombo-embolic events under anticoagulant therapy. <i>F1000Research</i> , 2013, 2, 189.	0.8	8
105	HMG improves IVF outcome in patients with high basal FSH/LH ratio: a preliminary study. <i>Reproductive BioMedicine Online</i> , 2009, 18, 205-208.	1.1	7
106	Placenta accreta spectrum in subsequent pregnancy following myomectomy. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 4332-4337.	0.7	7
107	Stop GnRH-Agonist Combined With Multiple-Dose GnRH-Antagonist Protocol for Patients With â€œGenuineâ€”Poor Response Undergoing Controlled Ovarian Hyperstimulation for IVF. <i>Frontiers in Endocrinology</i> , 2020, 11, 182.	1.5	7
108	Revisiting selected ethical aspects of current clinical in vitro fertilization (IVF) practice. <i>Journal of Assisted Reproduction and Genetics</i> , 2022, 39, 591-604.	1.2	7

#	ARTICLE	IF	CITATIONS
109	Serum androgen levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycles. <i>Gynecological Endocrinology</i> , 2005, 21, 218-222.	0.7	6
110	Is Day-4 morula biopsy a feasible alternative for preimplantation genetic testing?. <i>PLoS ONE</i> , 2020, 15, e0238599.	1.1	6
111	Stop GnRH-Agonist Combined with Multiple-Dose GnRH-Antagonist for Patients with Elevated Peak Serum Progesterone Levels Undergoing Ovarian Stimulation for IVF: A Proof of Concept. <i>Gynecologic and Obstetric Investigation</i> , 2020, 85, 357-361.	0.7	6
112	Does the number of embryos loaded on a single cryo-carrier affect post-vitrification survival rate?. <i>Zygote</i> , 2021, 29, 87-91.	0.5	6
113	A Novel Stimulation Protocol for Poor-Responder Patients: Combining the Stop GnRH-ag Protocol with Letrozole Priming and Multiple-Dose GnRH-ant: A Proof of Concept. <i>Gynecologic and Obstetric Investigation</i> , 2021, 86, 149-154.	0.7	6
114	Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for in vitro fertilization. <i>Fertility and Sterility</i> , 2014, 102, 1254-1255.	0.5	5
115	Triggering final follicular maturation: hCG, GnRH-agonist, or both, when and to whom?. <i>Journal of Assisted Reproduction and Genetics</i> , 2017, 34, 1231-1232.	1.2	5
116	“This is where it all started” the pivotal role of PLC γ within the sophisticated process of mammalian reproduction: a systemic review. <i>Basic and Clinical Andrology</i> , 2017, 27, 9.	0.8	5
117	Impact of the mode of conception on gestational hypertensive disorders at very advanced maternal age. <i>Reproductive BioMedicine Online</i> , 2020, 40, 281-286.	1.1	5
118	Does a Large (>24 mm) Follicle Yield a Competent Oocyte/Embryo?. <i>Gynecologic and Obstetric Investigation</i> , 2020, 85, 416-419.	0.7	5
119	Is There Any Association Between the Number of Oocytes Retrieved, Women Age, and Embryo Development?. <i>Reproductive Sciences</i> , 2021, 28, 1890-1900.	1.1	5
120	How Not to Introduce Laboratory Tests to Clinical Practice: Preimplantation Genetic Testing for Aneuploidy. <i>Clinical Chemistry</i> , 2022, 68, 501-503.	1.5	5
121	Soluble CD40 Ligand Levels during Controlled Ovarian Hyperstimulation “ A Possible Culprit of Systemic Inflammation. <i>American Journal of Reproductive Immunology</i> , 2006, 56, 243-248.	1.2	4
122	GnRH agonist versus GnRH antagonist in ovarian stimulation: has the ongoing debate resolved?. <i>Reproductive BioMedicine Online</i> , 2014, 29, 647-649.	1.1	4
123	Outcome of gestational surrogacy according to IVF protocol. <i>Journal of Assisted Reproduction and Genetics</i> , 2017, 34, 445-449.	1.2	4
124	Re-analysis of aneuploidy blastocysts with an inner cell mass and different regional trophoctoderm cells. <i>Journal of Assisted Reproduction and Genetics</i> , 2017, 34, 827-827.	1.2	4
125	Pregnancy and neonatal outcomes of twin pregnancies“ the role of maternal age. <i>Journal of Perinatal Medicine</i> , 2021, 49, 559-565.	0.6	4
126	Cleavage vs blastocyst stage embryos: how are they interrelating?. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1083-1088.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Does gonadotropin-releasing hormone agonist cause luteolysis by inducing apoptosis of the human granulosa-luteal cells?. <i>Journal of Assisted Reproduction and Genetics</i> , 2021, 38, 2301-2305.	1.2	4
128	The association between level of physical activity and pregnancy rate after embryo transfer: a prospective study. <i>Reproductive BioMedicine Online</i> , 2021, 42, 930-937.	1.1	4
129	GnRH-Agonist Ovulation Trigger in Patients Undergoing Controlled Ovarian Hyperstimulation for IVF with Stop GnRH-Agonist Combined with Multidose GnRH-Antagonist Protocol. <i>Gynecologic and Obstetric Investigation</i> , 2021, 86, 427-431.	0.7	4
130	A validated predictive model for adnexal torsion pre-operative diagnosis. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 1069-1077.	0.8	4
131	Controlled ovarian hyperstimulation: are we monitoring the appropriate sex-steroid hormones?. <i>Fertility and Sterility</i> , 2008, 89, 1269-1272.	0.5	3
132	The effect of female body mass index on in vitro fertilization cycle outcomes. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 2081-2081.	1.2	3
133	Sub-endometrial contractility or computer-enhanced 3-D modeling scoring of the endometrium before embryo transfer: are they better than measuring endometrial thickness?. <i>Journal of Assisted Reproduction and Genetics</i> , 2019, 36, 139-143.	1.2	3
134	Deliveries following fertility preservation by ovarian tissue cryopreservation without autotransplantation—what should be expected?. <i>Journal of Assisted Reproduction and Genetics</i> , 2019, 36, 335-340.	1.2	3
135	Can we predict oocyte maturation prior to denudation for intracytoplasmic sperm injection?. <i>Gynecological Endocrinology</i> , 2020, 36, 265-267.	0.7	3
136	The Effect of Ovarian Stimulation on Endothelial Function—A Prospective Cohort Study using Peripheral Artery Tonometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4722-e4729.	1.8	3
137	Testicular sperm retrieval: What should we expect from the fresh and subsequent cryopreserved sperm injection?. <i>Andrologia</i> , 2021, 53, e13849.	1.0	3
138	Can expelled cells/debris from a developing embryo be used for PGT?. <i>Journal of Ovarian Research</i> , 2021, 14, 104.	1.3	3
139	Transferring more than one embryo simultaneously is justifiable in most patients. <i>Reproductive BioMedicine Online</i> , 2022, 44, 1-4.	1.1	3
140	Comparison of effects of thawing entire donor sperm vial vs. partial thawing (shaving) on sperm quality. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 645-648.	1.2	2
141	The cost of a euploid embryo identified from preimplantation genetic testing for aneuploidy (PGT-A). <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 2077-2077.	1.2	2
142	Preimplantation embryos sex ratios in couples with four or more children of same sex, what should be expected from a preimplantation genetic diagnosis cycle?. <i>Gynecological Endocrinology</i> , 2019, 35, 515-517.	0.7	2
143	Spermatozoa retrieved by electroejaculation: Should we prefer fresh or cryopreserved spermatozoa for intracytoplasmic sperm injection?. <i>Andrologia</i> , 2020, 52, e13671.	1.0	2
144	How Are They Doing? Neurodevelopmental Outcomes at School Age of Children Born Following Assisted Reproductive Treatments. <i>Journal of Child Neurology</i> , 2021, 36, 262-271.	0.7	2

#	ARTICLE	IF	CITATIONS
145	“One-stop shop” for the evaluation of the infertile patient: hystero-salpingo foam sonography combined with two and three dimensional ultrasound and sonohysterography. <i>Journal of Obstetrics and Gynaecology</i> , 2022, 42, 670-674.	0.4	2
146	Albumin in the prevention of severe OHSS: Reply. <i>Human Reproduction</i> , 1999, 14, 1664a-1665.	0.4	1
147	Interleukin-1 beta production by human preimplantation embryos. <i>Journal of Assisted Reproduction and Genetics</i> , 1999, 16, 394-397.	1.2	1
148	Simplifying amniocentesis in paraplegic women—the wheelchair tilting manoeuvre. , 1999, 19, 1089-1090.		1
149	Serum P-selectin Level During Controlled Ovarian Hyperstimulation - a Preliminary Report. <i>American Journal of Reproductive Immunology</i> , 2004, 52, 139-142.	1.2	1
150	Human menopausal gonadotropin versus highly purified-hMG in controlled ovarian hyperstimulation for in-vitro fertilisation: does purity improve outcome?. <i>Gynecological Endocrinology</i> , 2010, 26, 733-735.	0.7	1
151	Human sperm aneuploidy: FISH analysis in fertile and infertile men. <i>Expert Review of Obstetrics and Gynecology</i> , 2011, 6, 609-627.	0.4	1
152	A man-made disease: Fetal neonatal alloimmune thrombocytopenia due to incompatibility between oocyte donor and gestational mother. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26447.	0.8	1
153	Timing day-3 vitrification for PGT-M embryos: pre- or post-blastomere biopsy?. <i>Journal of Assisted Reproduction and Genetics</i> , 2020, 37, 2413-2418.	1.2	1
154	Future fertility of patients with zero oocytes yield in their first IVF cycle attempt. <i>PLoS ONE</i> , 2021, 16, e0246889.	1.1	1
155	Dysregulation of anti-Mullerian hormone expression levels in mural granulosa cells of FMR1 premutation carriers. <i>Scientific Reports</i> , 2021, 11, 14139.	1.6	1
156	Cumulative IVF outcomes after retrieval of testicular spermatozoa: should we use immotile spermatozoa for ICSI?. <i>Reproductive BioMedicine Online</i> , 2021, 43, 269-277.	1.1	1
157	Fertility and pregnancy complications following chorioamnionitis. <i>Human Fertility</i> , 2021, , 1-4.	0.7	1
158	Pretreatment: Does it improve quantity or quality?. <i>Fertility and Sterility</i> , 2022, 117, 657-663.	0.5	1
159	The influence of urinary versus recombinant gonadotropin on serum P-selectin levels in vivo. <i>Gynecological Endocrinology</i> , 2005, 20, 185-187.	0.7	0
160	Comment on “The Role of Overweight and Obesity in In Vitro Fertilization Outcomes of Poor Ovarian Responders”. <i>BioMed Research International</i> , 2015, 2015, 1-1.	0.9	0
161	To pill or not to pill in GnRH antagonist cycles: what should be the appropriate wash-out period?. <i>Reproductive BioMedicine Online</i> , 2015, 30, 557.	1.1	0
162	Mono-ovulation in women with polycystic ovary syndrome: the role of step-up, ultra-low-dose gonadotrophin regimen. <i>Reproductive BioMedicine Online</i> , 2016, 33, 601-602.	1.1	0

#	ARTICLE	IF	CITATIONS
163	Do fertility treatments affect labor induction success rate? A retrospective cohort study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, , 1-5.	0.7	0
164	Do Follicles of Obese Patients Yield Competent Oocytes/Embryos?. <i>Gynecologic and Obstetric Investigation</i> , 2020, 85, 290-294.	0.7	0
165	How far is too far? Does time interval between GnRH antagonist and GnRH agonist trigger in GnRH antagonist cycles matter?. <i>Reproductive BioMedicine Online</i> , 2021, 43, 233-238.	1.1	0
166	The Influence of Cesarean Delivery on Ovarian Reserve: a Prospective Cohort Study. <i>Reproductive Sciences</i> , 2021, , 1.	1.1	0
167	Embryos derived from delayed mature oocyte should be cryopreserved and are favourable to transfer in a following endometrium synchronize frozen-thawed cycle. <i>Zygote</i> , 2022, 30, 689-694.	0.5	0